MX2009004519A - Sustancias que inhiben la glucolisis en un cultivo de celulas. - Google Patents

Sustancias que inhiben la glucolisis en un cultivo de celulas.

Info

Publication number
MX2009004519A
MX2009004519A MX2009004519A MX2009004519A MX2009004519A MX 2009004519 A MX2009004519 A MX 2009004519A MX 2009004519 A MX2009004519 A MX 2009004519A MX 2009004519 A MX2009004519 A MX 2009004519A MX 2009004519 A MX2009004519 A MX 2009004519A
Authority
MX
Mexico
Prior art keywords
protein
glycolysis
polypeptide
cell culture
grown
Prior art date
Application number
MX2009004519A
Other languages
English (en)
Inventor
Wenge Wang
Yen-Tung Luan
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2009004519A publication Critical patent/MX2009004519A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporciona un sistema mejorado para la producción a gran escala de proteínas y/o polipéptidos en un cultivo de células. De acuerdo con la presente invención, las células que expresan la proteína o polipéptido de interés son desarrolladas en medios que comprenden una sustancia que inhibe la glicólisis. Adicional y/o alternativamente, las células que expresan la proteína o polipéptido de interés se desarrollan en medios en los cuales se limita la glutamina. El uso de este sistema permite altos niveles de producción de proteína o polipéptido y reduce la acumulación de desperdicios metabólicos indeseables tal como lactato. Las proteínas y polipéptidos expresados de acuerdo con la presente invención pueden ser utilizados de manera ventajosa en la preparación de composiciones farmacéuticas, inmunógenas, agrícolas u otras composiciones comerciales.
MX2009004519A 2006-11-03 2007-11-02 Sustancias que inhiben la glucolisis en un cultivo de celulas. MX2009004519A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85661506P 2006-11-03 2006-11-03
PCT/US2007/083473 WO2008055260A2 (en) 2006-11-03 2007-11-02 Glycolysis-inhibiting substances in cell culture

Publications (1)

Publication Number Publication Date
MX2009004519A true MX2009004519A (es) 2009-05-12

Family

ID=39345103

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004519A MX2009004519A (es) 2006-11-03 2007-11-02 Sustancias que inhiben la glucolisis en un cultivo de celulas.

Country Status (7)

Country Link
US (1) US8192951B2 (es)
EP (2) EP2395077A1 (es)
JP (1) JP5401319B2 (es)
CA (1) CA2666317C (es)
ES (1) ES2541546T3 (es)
MX (1) MX2009004519A (es)
WO (1) WO2008055260A2 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1781700B1 (en) 2004-08-03 2014-03-19 TransTech Pharma, LLC Rage fusion proteins and methods of use
MY185872A (en) 2006-09-13 2021-06-14 Abbvie Inc Cell culture improvements
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
US9012180B2 (en) * 2007-03-02 2015-04-21 Wyeth Llc Use of copper and glutamate in cell culture for production of polypeptides
TWI610936B (zh) * 2008-10-20 2018-01-11 艾伯維有限公司 使用蛋白質ａ親和性層析進行抗體之分離及純化
MX2011004201A (es) 2008-10-20 2011-05-24 Abbott Lab Desactivacion viral durante purificacion de anticuerpos.
US9034341B2 (en) 2009-04-20 2015-05-19 Transtech Pharma, Llc Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions
US9096879B2 (en) * 2009-11-24 2015-08-04 Biogen Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
BR112012027434B1 (pt) 2010-04-26 2020-09-29 Novartis Ag Processo para produção de um polipeptídeo recombinante compreendendo uma fase de produção
KR101828624B1 (ko) 2010-04-26 2018-02-12 노파르티스 아게 개선된 세포 배양 방법
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2012147053A1 (en) 2011-04-29 2012-11-01 Biocon Research Limited A method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
SG11201401562RA (en) 2011-10-18 2014-09-26 Coherus Biosciences Inc Etanercept formulations stabilized with sodium chloride
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
BR112015000203A2 (pt) 2012-07-09 2017-06-27 Coherus Biosciences Inc formulações de etanercept que exibem redução marcada em partículas sub-visíveis
SG11201504249XA (en) 2012-09-02 2015-07-30 Abbvie Inc Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201501460RA (en) 2012-09-11 2015-04-29 Coherus Biosciences Inc Correctly folded etanercept in high purity and excellent yield
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015054554A1 (en) 2013-10-11 2015-04-16 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3099324B1 (en) 2014-01-30 2020-04-01 Coherus Biosciences, Inc. Perfusion media
PT3110961T (pt) 2014-02-27 2020-01-29 Hoffmann La Roche Modulação do crescimento celular e da glicosilação na produção de glicoproteínas recombinantes
US20160115225A1 (en) * 2014-10-24 2016-04-28 Abbvie Inc. Methods of Reducing Methylglyoxal (MGO) Modification of Recombinant Proteins in Cell Culture
SG10202002458PA (en) 2014-12-01 2020-04-29 Amgen Inc Process for manipulating the level of glycan content of a glycoprotein
WO2017015024A1 (en) 2015-07-20 2017-01-26 Mayo Foundation For Medical Education And Research Methods and materials for producing t cells
WO2023167852A2 (en) 2022-03-02 2023-09-07 Regeneron Pharmaceuticals, Inc. Cell culture methods for antibody production

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
EP0971033B1 (en) 1991-01-21 2009-10-28 Elan Pharmaceuticals, Inc. Test and model for Alzheimer's disease
DK1820858T3 (da) 1991-03-01 2009-11-02 Dyax Corp Kimært protein omfatende mikroprotein med to eller flere disulfidbindinger og udförelsesformer deraf
CA2108147C (en) 1991-04-10 2009-01-06 Angray Kang Heterodimeric receptor libraries using phagemids
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
CA2751712C (en) 1996-10-23 2016-11-22 The Trustees Of The University Of Pennsylvania Immunotherapy and improved vaccines
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
KR100942002B1 (ko) 1996-12-03 2010-02-12 암젠 프레몬트 인코포레이티드 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린 유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된 항체
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
EP1078093B1 (en) 1998-02-27 2011-06-08 The Trustees of The University of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
CN1197618C (zh) 1998-09-30 2005-04-20 惠氏控股有限公司 突变霍乱全毒素佐剂
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
CN1977971A (zh) 2001-06-07 2007-06-13 惠氏控股有限公司 作为佐剂的霍乱全毒素的突变体形式
CA2449670A1 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
DK2371392T3 (en) 2002-05-02 2015-08-31 Wyeth Holdings Llc Calicheamicin derivative / carrier conjugates
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
TWI374935B (en) * 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
US7300773B2 (en) * 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
US7294484B2 (en) * 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
SI2495307T1 (en) 2006-07-13 2018-05-31 Wyeth Llc Production of the calibration factor IX with an improved glycolization pattern
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation

Also Published As

Publication number Publication date
EP2064315A2 (en) 2009-06-03
JP2010508825A (ja) 2010-03-25
EP2395077A1 (en) 2011-12-14
JP5401319B2 (ja) 2014-01-29
CA2666317C (en) 2013-08-06
US8192951B2 (en) 2012-06-05
WO2008055260A2 (en) 2008-05-08
CA2666317A1 (en) 2008-05-08
EP2064315B1 (en) 2015-05-13
WO2008055260A3 (en) 2009-01-08
ES2541546T3 (es) 2015-07-21
US20080108106A1 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
MX2009004519A (es) Sustancias que inhiben la glucolisis en un cultivo de celulas.
MX2009009240A (es) Uso de cobre y glutamato en el cultivo celular para la produccion de polipeptidos.
MX2020011334A (es) Cultivo celular metabolicamente optimizado.
WO2012045082A3 (en) Engineered nucleic acids and methods of use thereof
Bechard et al. Subcellular localization of glycogen synthase kinase 3β controls embryonic stem cell self-renewal
WO2012135805A3 (en) Delivery and formulation of engineered nucleic acids
MX362028B (es) Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
WO2009091912A3 (en) Improved mammalian expression vectors and uses thereof
WO2015158808A3 (en) Recombinant host cell engineered to overexpress helper proteins
WO2011091350A3 (en) Methods & compositions for improving protein production
WO2011075686A3 (en) Methods & compositions comprising heat shock proteins
CA2782676C (en) Pharmaceutical compositions for intracellular delivery of nucleic acids and proteins and uses thereof for treatment of ureca cycle metabolic disorders
EP2598660A4 (en) COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN BLOOD AND OTHER BIODEGRADS DURING TRANSPORT AND STORAGE IN AMBIENT TEMPERATURES
WO2012056110A3 (en) Cell culture material based on microbial cellulose
WO2011130624A3 (en) Sustained polypeptide expression from synthetic, modified rnas and uses thereof
SG10201809152QA (en) Recombinant host cell for expressing proteins of interest
EP2641911A3 (en) Compositions and methods for re-programming cells without genetic modification
WO2009002456A3 (en) Methods and compositions relating to progenitor cells
MX2009004043A (es) Incorporacion genetica de aminoacidos no naturales a proteinas en celulas mamiferas.
GB2453068A (en) Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells
WO2010056808A3 (en) Compositions and methods for re-programming and re-differentiating cells
WO2011163531A3 (en) Compositions and methods for re-programming cells without genetic modification for treatment of cardiovascular diseases
WO2010031074A3 (en) Compositions and methods for regulating cell osmolarity
WO2009158627A3 (en) Cellulosic protein expression in yeast
WO2010068897A3 (en) Stem cell enhanced protein products and uses thereof

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal